David A. Cory - 11 Mar 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role: President and CEO, Director
Signature: /s/ Sriram Ryali, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 11 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 11 Mar 2022, 20:06:19 UTC
Previous filing: 30 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EIGR	Common Stock	Award	$0	+47,000	+38%	$0.000000	169,183	11 Mar 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EIGR	Stock Option (Right to Buy)	Award	$0	+281,000		$0.000000	281,000	11 Mar 2022	Common Stock	281,000	$5.10	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022.
F2	The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date.
F3	Includes shares purchased under the Issuer's Employee Stock Purchase Plans as follows: 1,378 shares on September 5, 2020, 1,459 shares on September 3, 2021, and 1,500 shares on March 5, 2022.